Efficiency and risks of laparoscopic conversion of omega anastomosis gastric bypass to Roux-en-Y gastric bypass.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
08 2019
Historique:
received: 02 04 2018
accepted: 17 10 2018
pubmed: 26 10 2018
medline: 6 5 2020
entrez: 25 10 2018
Statut: ppublish

Résumé

There is a paucity on literature data related to conversion of Omega anastomosis gastric bypass (OAGB) to Roux-en-Y gastric bypass (RYGB). This is a retrospective study. Records of all patients who underwent this conversion were analyzed. Additionally, patients were contacted to answer a questionnaire on their current clinical condition. Twenty-eight patients underwent laparoscopic conversion between September 2007 and June 2016. Indications were peritonitis in 7 patients (leaks after OAGB in 5, perforated marginal ulcer (MU) and blow-out remnant with concomitant leak in one patient each), anastomotic bleeding in one, bile reflux in 6, recalcitrant MU in 4, afferent loop syndrome in 6, postprandial vomiting in 2 (related to anastomotic stenosis and perianastomotic diverticulum, one each), and malnutrition and hypoglycemia both in 1. Thirty-day mortality was zero, complication rate (Clavien-Dindo grade III or more) 5% ((N = 1/20), abscess) when conversion was elective and 50.0% ((N = 4/8), all persisting leaks) when conversion was urgent. All 4 leaks persisting after conversion were successfully treated by endoscopic stenting, despite stent migration in 2 patients. Follow-up was available in 92.9%, for a mean time of 64.5 ± 30.1 months. Successful symptom relief (Likert score 4 or more) was noted for bile reflux and postprandial vomiting. Additionally, malnutrition was corrected. When indicated, conversion of OAGB to RYGB is a safe treatment strategy. In case conversion is performed for leak after OAGB, persisting subclinical leaks are frequent but can be efficiently addressed by endoscopic stenting.

Sections du résumé

BACKGROUND
There is a paucity on literature data related to conversion of Omega anastomosis gastric bypass (OAGB) to Roux-en-Y gastric bypass (RYGB).
METHODS
This is a retrospective study. Records of all patients who underwent this conversion were analyzed. Additionally, patients were contacted to answer a questionnaire on their current clinical condition.
RESULTS
Twenty-eight patients underwent laparoscopic conversion between September 2007 and June 2016. Indications were peritonitis in 7 patients (leaks after OAGB in 5, perforated marginal ulcer (MU) and blow-out remnant with concomitant leak in one patient each), anastomotic bleeding in one, bile reflux in 6, recalcitrant MU in 4, afferent loop syndrome in 6, postprandial vomiting in 2 (related to anastomotic stenosis and perianastomotic diverticulum, one each), and malnutrition and hypoglycemia both in 1. Thirty-day mortality was zero, complication rate (Clavien-Dindo grade III or more) 5% ((N = 1/20), abscess) when conversion was elective and 50.0% ((N = 4/8), all persisting leaks) when conversion was urgent. All 4 leaks persisting after conversion were successfully treated by endoscopic stenting, despite stent migration in 2 patients. Follow-up was available in 92.9%, for a mean time of 64.5 ± 30.1 months. Successful symptom relief (Likert score 4 or more) was noted for bile reflux and postprandial vomiting. Additionally, malnutrition was corrected.
CONCLUSIONS
When indicated, conversion of OAGB to RYGB is a safe treatment strategy. In case conversion is performed for leak after OAGB, persisting subclinical leaks are frequent but can be efficiently addressed by endoscopic stenting.

Identifiants

pubmed: 30353237
doi: 10.1007/s00464-018-6552-y
pii: 10.1007/s00464-018-6552-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2572-2582

Références

J Am Coll Surg. 2008 May;206(5):935-8; discussion 938-9
pubmed: 18471727
Surg Obes Relat Dis. 2016 Jul;12(6):1206-12
pubmed: 27320223
Obes Surg. 2001 Jun;11(3):276-80
pubmed: 11433900
Surg Obes Relat Dis. 2016 Feb;12(2):305-12
pubmed: 26410539
Obes Surg. 2015 Jun;25(6):951-8
pubmed: 25585612
Surg Endosc. 2014 Jan;28(1):156-63
pubmed: 23982648
Surg Endosc. 2016 May;30(5):2011-5
pubmed: 26194258
Surg Endosc. 2017 Feb;31(2):612-617
pubmed: 27317034
Ann Surg. 2005 Jul;242(1):20-8
pubmed: 15973097
Surg Obes Relat Dis. 2017 Jun;13(6):988-994
pubmed: 28223090
Obes Surg. 2013 Nov;23(11):1890-8
pubmed: 23934271
Surg Obes Relat Dis. 2015 Sep-Oct;11(5):1071-5
pubmed: 25868835
Surg Obes Relat Dis. 2016 Aug;12(7):1373-1381
pubmed: 27317605
Obes Surg. 2015 Oct;25(10):1976-8
pubmed: 26210192
Surg Obes Relat Dis. 2011 Sep-Oct;7(5):628-36
pubmed: 21798816
Surg Obes Relat Dis. 2017 Aug;13(8):1297-1305
pubmed: 28576683
Obes Surg. 2017 Sep;27(9):2222-2228
pubmed: 28361493
Obes Surg. 2015 May;25(5):805-11
pubmed: 25381115
Obes Surg. 2014 Sep;24(9):1520-7
pubmed: 24851857
Surg Endosc. 2013 Mar;27(3):808-16
pubmed: 23052499
Surg Endosc. 2016 Apr;30(4):1287-93
pubmed: 26130133
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
World J Gastroenterol. 2013 Oct 21;19(39):6590-7
pubmed: 24151386
Obes Surg. 2017 Sep;27(9):2279-2289
pubmed: 28405878
Surg Endosc. 2016 Jul;30(7):2935-45
pubmed: 26487198
Surg Endosc. 2015 Jun;29(6):1316-20
pubmed: 25294534
Surg Obes Relat Dis. 2007 Jan-Feb;3(1):37-41
pubmed: 17196443
J Minim Access Surg. 2012 Oct;8(4):118-24
pubmed: 23248437
Obes Surg. 2017 Aug;27(8):1952-1960
pubmed: 28303503
Obes Surg. 2018 Jan;28(1):161-168
pubmed: 28695460

Auteurs

Roel Bolckmans (R)

Department of Bariatric Surgery, AZ Sint-Blasius, Dendermonde, Belgium. roel_bolckmans@hotmail.com.

Gustavo Arman (G)

Department of Bariatric Surgery, AZ Sint-Blasius, Dendermonde, Belgium.

Jacques Himpens (J)

Department of Bariatric Surgery, AZ Sint-Blasius, Dendermonde, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH